May 20, 2020 by Austin McDaniel What about the use of plasma for treatment? According to the FDA: One investigational treatment being explored for COVID-19 is the use of convalescent plasma collected from individuals who have recovered from COVID-19. Convalescent plasma that contains antibodies to severe acute respiratory syndrome coronavirus 2 or SARS-CoV-2 (the virus that causes COVID-19) is being studied for administration to patients with COVID-19. Use of convalescent plasma has been studied in outbreaks of other respiratory infections, including the 2003 SARS-CoV-1 epidemic, the 2009-2010 H1N1 influenza virus pandemic, and the 2012 MERS-CoV epidemic. Although promising, convalescent plasma has not yet been shown to be safe and effective as a treatment for COVID-19. Therefore, it is important to study the safety and efficacy of COVID-19 convalescent plasma in clinical trials. For access to treatment with plasma, the FDA is allowing “single patient emergency use” for Severe or immediately life-threatening COVID-19 infections. There are hospitals in Alaska that have protocols in place for patients to receive plasma when ordered by their medical provider as part the individual care plan.